Neurofeedback, Self-Regulation, and Brain Imaging: Clinical Science and Fad in the Service of Mental Disorders

Robert T. Thibault\textsuperscript{a} Michael Lifshitz\textsuperscript{a} Niels Birbaumer\textsuperscript{c, d} Amir Raz\textsuperscript{a, b}

\textsuperscript{a}McGill University, and \textsuperscript{b}The Lady Davis Institute for Medical Research, Montreal, Que., Canada; \textsuperscript{c}Institute of Medical Psychology and Behavioral Neurobiology, University of Tübingen, Tübingen, Germany; \textsuperscript{d}Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale San Camillo, Venice, Italy

\section*{Introduction}

The science and practice of neurofeedback appeal to both researchers and practitioners. Neurofeedback gives real-time graphics or audio that reflect ongoing fluctuations in brain activity (fig. 1). This procedure propels participants to self-regulate otherwise volitionless neural function. The present article focuses on neurofeedback as a means to treating a variety of behavioral disorders (not the large corpus of literature dedicated to the development of brain-computer interfaces, BCIs, for immobilized patients [1]). Despite general enthusiasm, neurofeedback has yet to formally transition from the experimental laboratory to the larger clinical milieu. Here, we review the collective evidence concerning neurofeedback research: our account highlights the relative merits and current shortcomings of the field and charts a future path towards inclusion in the clinical armamentarium.

Neurofeedback developed from biofeedback in the 1960s and now draws on diverse imaging methods to help drive volitional control over electric, magnetic, and hemodynamic fluctuations in brain activity. Following the proliferation of biofeedback techniques targeting physiological parameters (e.g., skin conductance, heart rate, and blood pressure) [2], scientists began to investigate...
whether individuals could modify their electroencephalographic (EEG) brain signals. Researchers termed the subset of biofeedback techniques strictly concerned with altering brain signatures ‘neurofeedback’. The terms neurofeedback and EEG-biofeedback were once interchangeable. However, the proliferation of new methods for imaging the living human brain has vastly expanded the scope of neurofeedback, which today embraces novel techniques such as functional magnetic resonance imaging (fMRI), functional near-infrared spectroscopy (fNIRS), and magnetoencephalography (MEG). Within each imaging modality, moreover, researchers have developed distinct neurofeedback protocols that target different brain signals and concomitant physiological processes [3]. Whereas neurofeedback proponents sometimes lump together these diverse protocols, the findings support some techniques more than others. While high-profile journals focus on nascent feedback modalities and often disregard older techniques, publications on EEG-neurofeedback (EEG-nf) continue to outnumber reports on all other neurofeedback techniques combined (fig. 2).

Here, we conducted a comprehensive literature search using Web of Science™, Scopus, and Google Scholar with the query (neurofeedback OR biofeedback OR real-time) AND (EEG OR electroencephalograph* OR fMRI OR “functional magnetic resonance imaging” OR MEG OR magnetoencephalograph* OR fNIRS OR “near-infrared spectroscopy”). We include the most oft-cited and influential papers concerning each feedback modality. The present review illuminates the tenuous nature of much of the evidence surrounding EEG-nf and explores the potential merits of other newer feedback techniques.

Electroencephalographic Neurofeedback

When neurofeedback emerged in the 1960s, EEG was the only non-invasive device available to image the living human brain. Today, EEG remains the most common form of neurofeedback. Organizations such as The Biofeedback Certification International Alliance accredit EEG-nf practitioners, while The International Society for Neurofeedback and Research publishes journals centering on EEG-nf (i.e., the Journal of Neurotherapy from 1995 to 2013 and NeuroRegulation since 2014). This trend further extends to clinicians, who sometimes refer patients to neurofeedback practitioners offering expensive and time-consuming treatment regimens (table 1). Over dozens of sessions, participants develop implicit techniques to alter real-time representations of electrical fluctuations originating from their brain.

EEG-nf appears to effectively treat a range of psychological and neurological disorders [4–6]; however, it remains unclear how much the feedback itself as opposed to non-specific, placebo-like, factors mediate clinical improvements. While researchers originally leveraged EEG-nf to treat a narrow range of ailments including stress, epilepsy, and hyperkinesia, some now claim that this technique can improve a wide variety of disorders including developmental disabilities, traumatic brain injury, stroke, alcoholism, autism spectrum disorder, depression, insomnia, migraines, and chronic pain [4]. To date, however, only one double-blind study has documented greater clinical improvement in patients receiving verifiable EEG-nf (i.e., contingent on a signal of interest in their own brain) compared to sham-feedback (i.e., contingent on an unrelated signal from their own brain, activity from a different brain, or a random signal) [7]. Although EEG-nf researchers have reported post-training changes in objective measures including task performance, quantitative EEG [8–10], and resting-state fMRI [11, 12], these effects may result from non-specific variables including expectation, demand characteristics, and

Fig. 1. A conceptual diagram of neurofeedback.
contextual factors such as sitting attentively for extended periods of time – a behavior known to modulate brain function [13, 14]. Indeed, non-specific factors often propel very specific changes in both behavior and neural activity [15]. Here, we present and evaluate the research supporting EEG-nf as a clinical treatment. EEG-nf may well be an efficacious treatment; however, a close look at the collective literature challenges the tacit assumption that improvement is mostly attributable to the specific feedback of electrical potentials.

Table 1. Popularity, cost, and availability of neurofeedback modalities

<table>
<thead>
<tr>
<th></th>
<th>EEG</th>
<th>fMRI</th>
<th>MEG</th>
<th>fNIRS</th>
</tr>
</thead>
<tbody>
<tr>
<td>First application to neurofeedback</td>
<td>1958</td>
<td>2003</td>
<td>2005</td>
<td>2007</td>
</tr>
<tr>
<td>Practitioners worldwide, n</td>
<td>&gt;1,000</td>
<td>none</td>
<td>none</td>
<td>none</td>
</tr>
<tr>
<td>Research laboratories, n&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&gt;50</td>
<td>~10</td>
<td>3</td>
<td>~5</td>
</tr>
<tr>
<td>Cost of initial set-up, USD</td>
<td>500–5,000 (personal use)</td>
<td>500,000–2,000,000</td>
<td>2,000,000</td>
<td>50,000–300,000</td>
</tr>
<tr>
<td>Running costs, USD&lt;sup&gt;b&lt;/sup&gt;</td>
<td>no extra fees</td>
<td>~500/h</td>
<td>~500/h</td>
<td>no extra fees</td>
</tr>
<tr>
<td>Cost for patient, USD&lt;sup&gt;c&lt;/sup&gt;</td>
<td>130–225/session</td>
<td>not available to patients</td>
<td>not available to patients</td>
<td>not available to patients</td>
</tr>
<tr>
<td>Marketed equipment</td>
<td>many companies sell products for clinical, research, and personal uses</td>
<td>one software package for research use only</td>
<td>none (all laboratories run in-house software)</td>
<td>none (all laboratories run in-house software)</td>
</tr>
</tbody>
</table>

Currently, practitioners leverage only EEG-nf in the clinic. Alternatively, fMRI-, MEG-, and fNIRS-nf are costly and lack evidence for clinical application.

<sup>a</sup> This number does not include research laboratories dedicated solely to BCI research.

<sup>b</sup> Running costs based on fees charged at the Montreal Neurological Institute in Canada.

<sup>c</sup> Prices vary between centers. We report a representative price taken from an EEG-nf clinic in Austin, Tex., USA, and one in New York City, N.Y., USA.
Few EEG-nf experiments employ appropriate control conditions to determine whether feedback itself accounts for the clinical improvement. Many experiments use either no control group or a control condition that differs significantly from the target intervention in terms of length, intensity, and mode of training. And yet, neurofeedback may be particularly conducive to placebo effects because the training proceeds over dozens of sessions [16], involves expensive equipment [17], carries the allure of brain science [18], poorly blinds participants from experimenter expectation [19], and often aims to improve psychological rather than physiological conditions [20–22].

In the classical clinical trial, researchers randomly assign participants to one of two groups: one group receives veritable treatment (e.g., a drug or contingent neurofeedback), while the other group receives a seemingly similar treatment, yet one that contains no active element that is expected to affect physiology (e.g., a placebo pill or non-contingent feedback). Such trials are almost always double-blind (i.e., neither patients nor researchers are privy to group assignment). The difference in improvement between the two groups establishes the treatment effect: how much the drug itself, or the veritable feedback itself, actually improves a given condition. The changes observed in the sham-treated group encompass factors unrelated to the designated treatment mechanism. In EEG-nf studies, however, researchers rarely blind participants and seldom apply non-contingent feedback. Without a sham control group, researchers cannot establish the degree to which the designated mechanism is responsible for patient improvement.

Whereas some EEG-nf proponents claim that randomized placebo-controlled trials are impractical for neurofeedback experiments because they are complex and lengthy [23], let alone carry a non-negligible likelihood of breaking the blind [24], recent studies confirm the feasibility of rigorous sham-feedback-controlled studies [7, 25, 26]. A few single-blind experiments comparing neurofeedback to control treatments such as electromyography (EMG) biofeedback [27, 28] and sham EEG-nf [29, 30] demonstrated greater improvements in both healthy and patient populations in the veritable EEG-nf group. In contrast, recent studies showed that EEG-nf and EMG biofeedback were comparable for chronic pain [31], stroke rehabilitation [32], and attention deficit/hyperactive disorder (ADHD) [33]. Additional studies concerning pediatric ADHD have used stimulant medication as an active control, while attempting to maximize expectancy in both groups by allowing the parents of the affected children to select between medication and neurofeedback [34–36]. While participants in these experiments improved comparably regardless of treatment, a recent study randomly assigned participants to stimulant or neurofeedback treatment and revealed a greater effect in medicated participants [37]. Comparing a new therapy to a standard and accepted treatment is commonplace in clinical research and can provide clinical evidence for treatment efficacy. Nonetheless, only a placebo group (i.e., sham-feedback control) can isolate specific factors.

Notably, six of seven double-blind sham-controlled studies reported an absence of post-training behavioral difference between sham-feedback and veritable feedback groups [7, 25, 26, 38–41]. This outcome suggests that the benefits of EEG-nf may rely heavily on non-specific factors, including those associated with participating in research or meeting with a clinician, rather than on feedback per se. Yet, some EEG-nf proponents argue that the double-blind sham-controlled studies fail to provide a real neurofeedback treatment to either group [5]. They argue that such experimental designs may impinge on the effectiveness of neurofeedback by informing participants that they might receive sham-feedback [23] and by preventing clinicians from manually adjusting reward thresholds for each individual [5]. Without tailored feedback and assurance of veritable treatment, participants in both sham- and veridical-feedback groups may never develop a sense of control over their brainwaves and may, in turn, benefit only from non-specific factors. Thus, the double-blind sham-controlled studies to date have yet to confirm EEG-nf as either placebo- or feedback-driven. Alas, while EEG-nf does alter both brain patterns and behavioral measures, the current literature does not support a direct connection between the specific feedback and the observed alterations.

### Theta/Beta and Sensorimotor Rhythm Training

One of the first and now the most common clinical EEG-nf protocol, theta/beta training, emerged from a serendipitous finding that linked neurofeedback to seizure resistance in cats [42]. Researchers have since extended this protocol to human patients suffering from a variety of psychological disorders. A seminal paper demonstrated that a food-reward neurofeedback paradigm taught cats to down-regulate 12–15 Hz electrical activity over the sensorimotor cortex [42]. The authors identified this neural signature as a hallmark of attentive immobile states and coined the term sensorimotor rhythm (SMR)
to describe this pattern of activity [43]. Shortly thereafter, this research group reported that the cats who had undergone SMR training expressed delayed seizure onset when administered an epileptogenic compound [44]. SMR training soon expanded to human epileptics [45] and ADHD patients [46], both of whom demonstrated clinical improvements. Based on research associating increased theta amplitude with epileptiform activity and attention deficits [47], SMR training later developed into theta/beta training, which rewarded patients for increasing the SMR (12–15 Hz) or another subset of the beta bandwidth (12–21 Hz), while simultaneously decreasing theta activity (4–8 Hz) [48]. Patients undergoing theta/beta training also improved, although no experiment directly compared the effects of SMR to theta/beta training. While theta/beta training continues to dominate the neurofeedback literature today, researchers and practitioners have developed additional EEG-nf protocols that train different combinations of theta, alpha, and beta waveforms as well as brain electronegativity [49] (i.e., slow cortical potentials, SCPs), isolated brain regions [50], or any deviation from a normalized brain [51, 52] (table 2).

![Table 2. Common EEG-nf protocols and applications](image)

<table>
<thead>
<tr>
<th>Training protocol</th>
<th>Target neural signature</th>
<th>Common applications</th>
<th>Principal evidence (observable changes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theta/beta</td>
<td>↑ subset of 12–21 Hz (12–15 Hz is SMR training) ↓ 4–8 Hz</td>
<td>ADHD, epilepsy</td>
<td>ADHD rating scales, seizure frequency, resting-state EEG, resting-state fMRI</td>
</tr>
<tr>
<td>SCP</td>
<td>↑ and ↓ resting-state electronegativity</td>
<td>ADHD, epilepsy</td>
<td>subjective measures, resting-state EEG, resting-state fMRI, seizure frequency</td>
</tr>
<tr>
<td>Upper/peak alpha</td>
<td>↑ alpha frequency that is already largest in amplitude (often 9–11 Hz)</td>
<td>athletic and cognitive performance</td>
<td>intelligence tests</td>
</tr>
<tr>
<td>Low resolution electromagnetic tomography</td>
<td>↑ or ↓ activity of select brain regions (often the anterior cingulate)</td>
<td>cognitive enhancement</td>
<td>intelligence tests</td>
</tr>
<tr>
<td>Theta+alpha</td>
<td>↑ 4–13 Hz</td>
<td>alcoholism</td>
<td>prevention of relapse</td>
</tr>
<tr>
<td>Theta/alpha</td>
<td>↑ 4–8 Hz ↓ 8–13 Hz</td>
<td>creativity</td>
<td>artistic performance</td>
</tr>
<tr>
<td>Live z scorea</td>
<td>normalize the amplitude and coherence of all waveforms (visual and auditory feedback)</td>
<td>any disorder</td>
<td>subjective measures</td>
</tr>
<tr>
<td>Low energy neurofeedback systemb</td>
<td>normalize the amplitude and coherence of all waveforms (electrical pulse feedback)</td>
<td>any disorder</td>
<td>subjective measures</td>
</tr>
</tbody>
</table>

a The last two trainings are commercial techniques.

Theta/beta training is the only EEG-nf technique that researchers have tested for specificity. A few EEG-nf proponents derived contentious conclusions from studies in which experimenters reversed reward contingency as a sham comparator (i.e., receiving the same positive feedback for producing exactly the opposite brain activity). If symptoms worsen, then the specific feedback likely accounts for behavioral changes; alternatively, if patients improve similarly regardless of the feedback received, non-specific factors likely mediate clinical effects. The claim that improved symptomatology depends on specific reward contingencies hinges on one case study of ADHD [46] and two experiments with 8 epileptics [48, 53]. These experiments used a 'veritable-sham-veritable' design. Over the course of 3 months, patients first trained to increase the theta/beta ratio (veritable condition), then to decrease the same ratio (inverse-sham condition), and finally to increase it once again. Data from these oft-cited studies, dating back to the late 1970s, scantily substantiate the reported conclusions. In one study, 3 patients had fewer seizures when receiving veritable feedback compared to inverse-sham information;
however, 5 patients experienced more seizures in the ver-
itable-feedback condition [53]. In the other experiment, 5 of 8 patients improved with veritable theta/beta train-
ing, and 4 of 8 improved in the sham-inverse condition [48]. Training was successful only in that, on average, patients reported decreased seizures after all training was complete. In contrast to the authors’ interpretations, therefore, these data do not support the specificity of the-
ta/beta training.

Examining data for clinical conditions such as ADHD and epilepsy, neurofeedback seems to work but perhaps through untargeted processes. A few meta-analyses and reviews promote clinical theta/beta training; however, the majority of included studies are not designed to test specificity. One meta-analysis of theta/beta training for ADHD claimed that EEG-nf is ‘efficacious and specific’ [54], yet not one of the 14 included studies employed a sham-feedback control group. Instead, the studies used stimulants, wait-listed controls, EMG feedback, group therapy, or no control group. Moreover, most experi-
ments did not blind participants or researchers. Five years later, a follow-up review [5] cited new literature leveraging semi-active, active, and placebo control groups. While the authors presented findings that pro-
mote the efficacy of neurofeedback compared to muscle biofeedback, medication, and computerized training, they noted that sham-feedback studies had yet to con-
firm the importance of contingent feedback. Another re-
view concluded EEG-nf is ‘probably efficacious’ for pe-
diatric ADHD [55]. Of the 14 studies included, eight had not undergone peer-review, two used wait-list controls, two employed group therapy, one had no control, and only one used sham-feedback. Moreover, the single sh-
am-feedback study reported that both contingent and non-contingent feedback comparably improved ADHD symptomatology [56]. Regarding epilepsy, a recent me-
ta-analysis claimed that EEG-nf is ‘efficacious and spe-
cific’ for decreasing seizure occurrence [6]. Of the ten studies included, however, three conduct multiple treat-
ments without isolating the effects of EEG-nf and three state that placebo effects drove clinical outcomes. Thus, the collective evidence indicates that theta/beta training offers an efficacious, yet non-specific, treatment for both ADHD and epilepsy.

Conceptually, confusion lingers as to the use of basic concepts such as the SMR. Since 1981, no published EEG-
NF experiment has reversed reward contingency, yet many researchers and practitioners continue to assert that the type of feedback specifically determines treatment out-
comes [4, 57]. The SMR is defined as a signature of atten-
tive motor-inhibiting states [43] – the same states as-
sumed throughout EEG-nf. Sitting still for long training
periods likely improves motor inhibition, which in turn may increase SMR amplitude. Thus, theta/beta training
may teach participants to regulate cortical activity through non-specific factors. Notably, the literature also lacks ev-
idence demonstrating parallels in post-training EEG fluc-
tuations and clinical improvement.

Other EEG-nf Protocols

Some researchers and practitioners focus on EEG-nf protocols concerned with self-regulation of brain signals unrelated to theta/beta training. The second most popu-
lar technique aims to train brain electromagnetivity or elec-
tropositivity via SCPs. The neurophysiological basis of SCP is much better described than most other EEG sig-
natures [58]. Some studies report that SCP-nf can reduce seizure frequency [24, 59] and, after extensive training, allow locked-in patients to communicate through a BCI [60]. Yet, relevant studies share many of the same meth-
odological shortcomings as experiments on theta/beta training and a recent review concluded that specificity remains unsupported [47].

Over the past decade, researchers popularized upper, or ‘peak’, alpha training to improve cognitive perfor-
mance [61, 62]. While training propelled cognitive im-
provement in many participants, the studies lacked active control groups, and instead employed wait-list controls [63], controls who sat passively during feedback sessions [64], or no controls at all [65–67]. Moreover, some studies divided their participants into responders and non-re-
sponders, thus inflating the results [64, 66]. Interestingly, only individuals with a lower baseline alpha frequency, constituting 70% of participants, successfully increased alpha power. As often observed in psychological thera-
pies [68], neurofeedback may affect some individuals more than others. Future experiments that pre-screen participants and successfully select a responsive sample may bolster the evidence promoting upper alpha training. While proponents of this technique have commented that the range of methodologies used to train upper alpha activity makes double-blind sham-controlled studies prohibitively difficult [69], researchers have already suc-
cessfully conducted such studies [38]. Some researchers further argue that individuals must train personalized frequency bands or else risk potential cognitive detriment [61]. Such claims, however, largely rely on case studies and anecdotal evidence [70, 71].
A handful of other EEG-nf protocols attempt to improve particular disorders or behavioral traits, but few of the relevant experiments have employed adequate control groups, while blinding both participants and experimenters. For example, low resolution electromagnetic tomography-nf aims to train isolated brain regions to improve intelligence [50]; increasing both alpha and theta activity (theta-alpha training) aims to treat alcoholism [72]; and increasing theta relative to alpha (theta/alpha training) supposedly enhances creative performance [73] (table 2). See Gruzelier [62] for a review of performance optimization neurofeedback. Finally, a few contentious commercial applications undercut the credibility of EEG-nf. Live z score training and the low energy neurofeedback system aim to normalize EEG waveforms in relation to a database of resting-state recordings from healthy controls. These techniques lack both a clear physiological basis and support from the mainstream neurofeedback community.

After 50 years of research, EEG-nf has largely failed to breakthrough into routine clinical care. The various forms of electrical feedback appear to lend participants mild control over select brain signatures, while therapeutic effects seem to derive largely from non-specific factors. These conclusions encourage novel research directed at teasing apart the non-specific factors, which contribute to improvement as well as the circumstances and mechanisms that subserve them. Researchers and clinicians would be able to leverage such knowledge to foster new and effective treatments to utilize both the specific and non-specific facets of EEG-nf training.

Emerging Neurofeedback Techniques

Until about a decade ago, EEG was the only available neurofeedback modality. In recent years, however, novel imaging techniques and increased computational power have offered researchers new forms of feedback that draw on diverse brain signals reflecting various underlying neural processes (fig. 3).

Current neurofeedback modalities fall into two broad categories: electromagnetic and hemodynamic training. Whereas EEG and MEG record electromagnetic activity originating from pyramidal cells in superficial cortical regions, fMRI and fNIRS measure local oxygenated and deoxygenated blood concentrations correlated with ongoing neural activity. EEG and MEG have poor spatial resolution but millisecond temporal resolution; fMRI has millimeter spatial resolution yet poor temporal resolution, and fNIRS has poor resolution both spatial and temporal. These intrinsic differences lend select imaging methods to particular applications. For example, because seizure onset alters electrical brain patterns, some researchers promote EEG-nf training as a tool to inhibit pre-epileptic brain states and prevent seizure occurrence [6]. Alternatively, conditions associated with alterations in deep brain functions (e.g., chronic pain and the anterior cingulate cortex) may benefit from imaging methods unrestricted by depth such as fMRI [74]. Examining such strengths and weaknesses may help researchers apply appropriate neurofeedback techniques to specific applications.

Feedback methods also differ in feasibility and availability (table 1). Researchers and practitioners can quickly learn to conduct EEG-nf with a modest budget using a variety of commercially available software packages and hardware systems. Alternatively, fMRI- and MEG-nf are available to fewer researchers because single imaging sessions cost over USD 500/h and because such imaging methods require dedicated state-of-the-art facilities typically found in large institutions rather than in smaller groups. MEG- and fNIRS-nf, moreover, demand considerable technical expertise because no standard or off-the-shelf software packages are available to facilitate these novel, computation-heavy, protocols.

As novel neurofeedback modalities developed from EEG-nf, researchers acknowledged earlier experimental shortcomings and attempted to apply more robust designs to better decipher specific effects. Crucially, in contrast to the classical neurofeedback literature, newer studies tend to employ sham-feedback control groups. Furthermore, nascent neurofeedback techniques may generate smaller placebo effects because they require fewer sessions, in turn, reducing demand characteristics, interactions with a healer, and treatment intensity. While some researchers might argue that longer trials would reduce placebo effects – which are sometimes viewed as short and transient – recent evidence demonstrates that benefits from non-specific treatments can persist for long durations, from weeks to years [20, 75, 76]. The short duration of training also obviates ethical concerns regarding prolonged sham treatment. On the flip side, most cognitive interventions exhibit strong dose-effect relationships – thus, longer trials may intensify both specific and non-specific effects of neurofeedback. The emerging wave of neurofeedback research strives to advance the field in terms of both training efficacy and scientific rigor.
Functional Magnetic Resonance Imaging

fMRI-nf, often referred to as real-time fMRI of rtfMRI, outputs ongoing data concerning blood oxygen concentrations from any region in the brain. In 2005, deCharms et al. [74] published an fMRI-nf study that employed a careful design and reported robust findings, sparking enthusiasm for this seemingly promising technique. The experiment demonstrated that chronic pain patients who received veritable feedback could learn to modulate rostral anterior cingulate cortex (ACC) activity. Moreover, patients could continue to down-regulate the ACC in the absence of feedback, and these neural deactivations paralleled decreases in subjective pain. Such effects were absent in control participants who received feedback from a different brain region or the brain of another participant, or who trained without neurofeedback. This well-controlled study remains the strongest piece of evidence supporting fMRI-nf as an effective tool for self-regulating the brain and improving clinical conditions. However, the impact of this one promising study has become shrouded by decade-long skepticism; question marks have turned into
exclamation points after a string of independent replication efforts, including by the original authors, was unable to corroborate the reported findings [77, 78].

In the aftermath of this problematic study by deCharms et al. [74], most fMRI-nf accounts seldom probe behavioral change but rather report proof-of-concept experiments, demonstrating that participants can alter their blood flow to select cortical regions. All but two [79, 80] of the dozens of published fMRI-nf studies suggested that participants can learn to modulate brain hemodynamics within 40 min. Eight fMRI-nf experiments employed sham-feedback controls and demonstrated that participants increased their ability to modulate a particular brain region throughout training [81–90]. In contrast, the dozens of remaining studies lacked necessary controls or appropriate analyses to specify neurofeedback as the primary determinant of the observed brain alterations. Indeed, a recent report demonstrated that participants receiving sham-neurofeedback expressed increased activation of the bilateral insula, ACC, motor areas, and prefrontal areas [91]. Notably, these are the four most common regions trained in fMRI-nf experiments. Thus, only designs that include a sham-feedback control condition can isolate the specific benefits of fMRI-nf.

While EEG-nf takes dozens of sessions to alter electrical activity, fMRI-nf often allows individuals to selectively modify their cortical blood flow within a single half-hour session. In fact, participants in some fMRI-nf studies can modulate their brain in the first trial [92–96]. Thus, experimental designs that lack a no-feedback or sham-feedback control cannot dissociate whether the change from baseline relies on feedback or the initial mental strategy. In a yet-to-be-published fMRI-nf experiment, deCharms targeted this question. He demonstrated that participants given explicit mental strategies successfully learned brain self-regulation, whereas individuals instructed to develop implicit techniques did not [77]. Furthermore, two studies comparing veridical feedback with no feedback [96] or inversely proportional feedback [95] revealed equivalent neural changes from baseline to the first trial. These findings may suggest that initial mental strategies are at least partly responsible for the rapid changes in fMRI signal. Alternatively, a few studies using both humans and animals suggest that explicit techniques are unnecessary and that contingent feedback alone suffices to develop neural regulation [97, 98]. Hemodynamic learning may occur more quickly because, while the brain lacks receptors that track electrical changes associated with EEG, baroreceptors constantly inform the central nervous system about ongoing blood volume relevant to fMRI. While this view remains highly speculative, a series of experiments demonstrating operant conditioning of baroreceptor activation in rats provide preliminary support [99]. Regardless of the cause, the collective evidence indicates that individuals can learn to modulate hemodynamics faster than electrical fluctuations.

Few fMRI-nf studies test whether participants can continue to modulate brain activity after the researchers remove feedback. Whereas some experiments demonstrate that participants retain control over target brain regions [81, 86, 89, 100] other studies report no retention [93, 95, 101–103]. Thus, while findings suggest that fMRI-nf might help individuals learn to modulate select brain regions, whether participants retain this ability after training remains tenuous.

Whereas fMRI-nf researchers often emphasize potential clinical applications, only sparse accounts have attempted to correlate neurofeedback training with changes in perception or behavior. For example, volitionally dampening ACC activity appears to decrease cigarette cravings [92, 104]; modulating insular activity affects the perceived valence of emotional stimuli [82, 101]; altering prefrontal blood flow can improve the detection of emotional prosodic intonations [85] and verbal working memory [105], and training motor areas can improve motor control in Parkinson’s patients [100]. While the neurofeedback itself may account for some of these outcomes, many of the relevant experiments would require more robust controls before ascertaining specificity. Both experiments on smoking cessation [92, 104] lacked a neutral baseline and instead compared only conditions when participants attempted to enhance craving without neurofeedback versus inhibit craving with neurofeedback. Thus, we cannot conclude whether neurofeedback or mental strategies accounted for the decreased desire to smoke. Furthermore, the experiment on working memory demonstrated that sham-neurofeedback enhanced performance on four of the five working memory tasks, even while actually impairing the ability to modulate target brain regions. Neither the emotional valence study with schizophrenics [101] nor the experiment with Parkinson’s patients [100] included a sham-feedback control. The Parkinson’s patients, moreover, engaged in additional training outside the context of neurofeedback. Finally, the largest fMRI-nf study conducted to date (59 participants) demonstrated that mental rehearsal and neurofeedback treat chronic pain equivalently; yet the report remains unpublished [77]. Thus, while fMRI-nf appears to influence brain activity, applying this technique to modulate specific behaviors requires more rigorous investigation.

Neurofeedback: Clinical Science and Fad
Functional Near-Infrared Spectroscopy

fNIRS probes the same underlying hemodynamics as fMRI [106], yet possesses distinct strengths and weaknesses when applied to neurofeedback. On the one hand, fNIRS is relatively inexpensive, impervious to movement artifacts, and portable throughout daily activities. On the other hand, whereas fNIRS offers spatial resolution on the order of centimeters at surface regions only, fMRI provides millimetric precision throughout the brain. Moreover, unlike the sparse clinical fNIRS literature, an expansive body of research already links fMRI neural signatures with various disorders.

To date, most fNIRS-nf researchers have focused on altering control over surface motor regions. Four recent studies suggested that participants can use fNIRS-nf to increase activity in a variety of motor areas [107–110]. These experiments were particularly susceptible to non-specific factors because participants can modulate motor cortex activity without neurofeedback – by simply moving a limb or covertly tensing a muscle. In these experiments, participants imagine tapping a finger or clenching a hand. Yet, the researchers omitted testing EMGs in the arm to detect covert tensing. Therefore, discreet, possibly subconscious, muscle tension in the arm or hand may have accounted for increases in neural activity.

In two of the four recent fNIRS-nf studies, participants receiving veritable feedback improved modulation over a specific motor region better than sham controls [107, 109]. In these experiments, contingent feedback appears responsible. The veritable feedback may, however, teach participants to unknowingly increase muscle tension rather than develop new mental techniques. Furthermore, a recent experiment demonstrated that sham-feedback enhances self-regulation of the fNIRS signal over the motor cortex [111]. The last study lacks a control group [108].

Numerous papers propose fNIRS as a promising modality for use in BCIs. The available evidence supports the efficacy of fNIRS BCIs [112, 113]. Yet, this technique does not teach participants to alter brain activity via neurofeedback; rather, individuals simply assume two mental states, while the device learns to classify the data. Therefore, fNIRS BCIs are mostly irrelevant to arguments supporting neurofeedback as a mechanism for gaining volitional control over brain dynamics.

Magnetencephalography

MEG-nf is still rare, requiring expensive and sparsely available imaging equipment. Similar to EEG, MEG provides a direct measure of neural activity. In contrast to the smearing of EEG signals when crossing the skull and cephalic tissues, however, magnetic fields arrive at the sensors relatively undisturbed. Thus, MEG boasts an impressive spatial resolution and signal-to-noise ratio and may prove especially useful for applications requiring combined spatial and temporal specificity of cortical regions.

Healthy participants using MEG-nf learned bidirectional control over their SMR (often called the mu-rhythm in MEG research) within 64 min [114] and over disparate motor cortex activations within 32 min [115]. Similar to fNIRS-nf experiments, participants could have unknowingly engaged limb muscles to increase cortical activation. Indeed, stroke patients, who have less control over limb flexion, took much longer – 13–22 sessions of 1–2 h – to gain control over the MEG signal [116]. Furthermore, despite research efforts from several independent groups, completely locked-in patients, without control over body muscles, have been largely unsuccessful in maintaining control over neuroimaging signals [117] – save for one recent case study employing an fNIRS BCI combined with aversive stimuli [118]. Nonetheless, locked-in patients who retain some mobility have learned to communicate via EEG BCIs [60]. Altogether, therefore, subconscious muscle tension, rather than neurofeedback-assisted mental techniques, may account for the improved control over magnetic brain signals. While initial reports sparked enthusiasm, future studies with robust controls would be necessary to confirm MEG-nf as an effective technique to learn brain control.

Future Directions

While neurofeedback has undergone a vigorous revival over the past decade, our review highlights a host of methodological and interpretational caveats that pervade the literature. Although some clinicians already refer patients to practitioners of EEG-nf, the collective findings suggest that this technique scarcely outperforms placebo. The breadth of neurofeedback techniques, however, has greatly expanded with the advent of novel real-time imaging modalities including fMRI, fNIRS, and MEG. Moreover, new studies incorporating increasingly robust experimental designs have begun to unravel the
specificity of neurofeedback. And yet, the influence of neurofeedback on behavior remains uncertain. Thus, if neurofeedback is to gain a solid footing in clinical practice, it would behoove researchers to focus on demonstrating both specificity and therapeutic outcome.

First, researchers could conduct and replicate well-designed studies to probe whether the feedback itself, rather than placebo factors, accounts for neural changes. Ideally, these experiments would employ three control groups (i.e., sham-feedback from another participant, feedback from an unrelated brain region, and mental strategy rehearsal) while also collecting subjective data (e.g., what type of feedback participants thought they were receiving, their level of motivation throughout training, how they felt about their performance, and whether they believed the protocol would work). In addition, these studies could implement a double-blind design to minimize the influence investigator knowledge exerts over outcomes. With such designs, researchers could more easily disentangle specific and non-specific factors. More well-controlled studies of this ilk, similar to the landmark experiment by deCharms et al. [74], could bolster evidence to support neurofeedback as a viable tool for brain regulation. Conforming to such stringent methods, one recent study controlled for placebo effects and obtained encouraging results [7].

Second, researchers could aim to demonstrate behavioral or clinical relevance. Since 1996, certification boards have accredited clinical neurofeedback practitioners, yet only one study to date demonstrates greater clinical improvement from EEG-nf compared to sham-feedback [7]. Moreover, few fMRI-nf experiments directly probe therapeutic outcomes. Some clinicians, nonetheless, refer patients to neurofeedback training programs that last more than 6 months, include as many as 40 sessions, and generally cost between USD 4,000 and 10,000 (table 1). To ensure that patients receive fair treatment for their time and money, future sham-controlled studies could measure therapeutic outcomes and conduct follow-up sessions. Furthermore, researchers could measure whether differences in neural control parallel changes in behavior. Such findings would support the supposition that brain self-regulation influences clinical behavior.

Developing neurofeedback techniques that target functional connectivity may improve the precision of brain control and engender distinct behavioral results. Researchers have documented altered functional networks in patients with ADHD, depression, schizophrenia, and a host of other disorders [119]. Moreover, collaborative international efforts such as The Human Connectome Project strive to catalog anatomical and functional connectivity throughout the human brain and map out the associated functions. Mounting evidence suggests that many complex behaviors rely on the coordinated activity of multiple regions distributed across functional networks [120]. For neurofeedback, therefore, targeting single regions as opposed to large-scale networks may restrict the ability to hone in on specific behaviors. While network-based neurofeedback presents particular technical challenges, one research group has recently trained participants to modulate connectivity between the visual and parietal cortex [94].

Providing a reward contingent on a combination of signals from multiple simultaneous imaging modalities may also increase the effectiveness of neurofeedback. Recently, a proof-of-concept experiment has combined real-time fMRI- and EEG-nf to guide healthy participants to concurrently modulate left amygdala activity and frontal EEG power asymmetry [93]. While such prospects face the same methodological challenges as more conventional forms of neurofeedback, they open new avenues for unlocking the powers of the self-regulating brain.

Conclusion

Scrutinizing relevant findings, we perused the available studies to find evidence largely against the clinical promise of EEG-nf but perhaps with more hopeful prospects for fMRI and other imaging modalities. Regardless of what we found, neurofeedback is in vogue. Pertinent publications abound as feedback techniques continue to advance in parallel with new imaging methods and faster computations. Many researchers and practitioners promote real-time brain feedback as an effective treatment option. Contrary to common opinion, our review of the literature on EEG-nf suggests that treatment outcomes are likely attributable to placebo responses and placebo effects. Moreover, experiments obtaining null-results often shy away from publication, thereby misrepresenting the ratio of negative to positive findings [121]. Mandatory registration of neurofeedback research, as federal drug administrations require for all clinical trials, may obviate this concern, highlight publication bias, and provide data for inclusive meta-analyses. Yet, if EEG-nf consistently outperforms standard treatments requiring comparable investment of time and money, neurofeedback may triumph as a therapeutic option regardless of whether the benefits derive from specific or non-specific factors. In practice, any patient-therapist interaction draws on psychosocial parameters such as hope, motiva-
neurofeedback techniques, including tNIRS- and MEG-nf, still need to evolve and amass sufficient evidence to warrant claims promoting their efficacy. Thus, while neurofeedback research continues to flourish, compelling data remain sparse.

We hope the present review provides a valuable resource to researchers and clinicians committed to unravelling the intricacies of the self-regulating brain. Adopting a critical lens can only help neurofeedback to live up to popular lore and transition to the mainstream clinical milieu. As imaging technologies mature and experimental techniques fine-tune, the exciting field of neurofeedback will either change the way we do mind-body cognitive neuroscience or drown out as a fad. As clinical researchers who examine the available evidence, we dread the latter but earnestly hope for the former.

**Acknowledgements**

Dr. Amir Raz acknowledges funding from the Canada Research Chair program, Discovery and Discovery Acceleration Supplement grants from the Natural Sciences and Engineering Research Council of Canada (NSERC), Canadian Institutes of Health Research, and the Volkswagen Foundation (VolkswagenStiftung). Michael Lifshitz acknowledges a Francisco J. Varela Research Award from the Mind and Life Institute and a Vanier Canada Graduate Scholarship from NSERC.

**References**


Neurofeedback: Clinical Science and Fad


